This announcement is a separate document:
哈三联：北京市中伦律师事务所关于哈尔滨三联药业股份有限公司2022年限制性股票激励计划第一个解除限售期解除限售条件成就、调整回购价格及回购注销部分限制性股票相关事项之法律意见书
Harbin Sanlian: Legal Opinion of Beijing Zhonglun Law Firm on Harbin Sanlian Pharmaceutical Co., Ltd.\'s 2022 Restricted Stock Incentive Plan on matters relating to the first lifting of sales restrictions period and lifting of sales restrictions conditions
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.